K
Kate R. Woodworth
Researcher at Centers for Disease Control and Prevention
Publications - 45
Citations - 1897
Kate R. Woodworth is an academic researcher from Centers for Disease Control and Prevention. The author has contributed to research in topics: Medicine & Pregnancy. The author has an hindex of 7, co-authored 18 publications receiving 864 citations.
Papers
More filters
Journal ArticleDOI
Characteristics of Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status - United States, January 22-June 7, 2020.
Sascha R. Ellington,Penelope Strid,Van T. Tong,Kate R. Woodworth,Romeo R. Galang,Laura D. Zambrano,John F. Nahabedian,Kayla N. Anderson,Suzanne M. Gilboa +8 more
TL;DR: It is suggested that among women of reproductive age with COVID-19, pregnant women are more likely to be hospitalized and at increased risk for ICU admission and receipt of mechanical ventilation compared with nonpregnant women, but their risk for death is similar.
Journal ArticleDOI
Birth and Infant Outcomes Following Laboratory-Confirmed SARS-CoV-2 Infection in Pregnancy - SET-NET, 16 Jurisdictions, March 29-October 14, 2020.
Kate R. Woodworth,Emily O'Malley Olsen,Varsha Neelam,Elizabeth L. Lewis,Romeo R. Galang,Titilope Oduyebo,Kathryn Aveni,Mahsa M. Yazdy,Elizabeth Harvey,Nicole D. Longcore,Jerusha Barton,Chris Fussman,Samantha Siebman,Mamie Lush,Paul H. Patrick,Umme Aiman Halai,Miguel Valencia-Prado,Lauren Orkis,Similoluwa Sowunmi,Levi Schlosser,Salma Khuwaja,Jennifer S. Read,Aron J. Hall,Dana Meaney-Delman,Sascha R. Ellington,Suzanne M. Gilboa,Van T. Tong +26 more
TL;DR: Findings can inform neonatal testing recommendations, clinical practice, and public health action and can be used by health care providers to counsel pregnant women on the risks of SARS-CoV-2 infection, including preterm births.
Journal ArticleDOI
Candida auris: The recent emergence of a multidrug-resistant fungal pathogen.
Kaitlin Forsberg,Kate R. Woodworth,Maroya Spalding Walters,Elizabeth L. Berkow,Brendan R Jackson,Tom Chiller,Snigdha Vallabhaneni +6 more
TL;DR: The global emergence, biology, challenges with laboratory identification, drug resistance, clinical manifestations, treatment, risk factors for infection, transmission, and control of C. auris are reviewed.
Journal ArticleDOI
The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5-11 Years - United States, November 2021.
Kate R. Woodworth,Danielle Moulia,Jennifer P Collins,Stephen C. Hadler,Jefferson M. Jones,Sujan Reddy,Mary Chamberland,Doug Campos-Outcalt,Rebecca L. Morgan,Oliver Brooks,H. Keipp Talbot,Grace M. Lee,Beth P. Bell,Matthew F. Daley,Sarah Mbaeyi,Kathleen Dooling,Sara E. Oliver +16 more
TL;DR: The Pfizer-BioNTech COVID-19 (BNT162b2) vaccine is a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine encoding the prefusion spike glycoprotein of SARS-CoV-2, the virus that causes COVID19 as discussed by the authors.
Journal ArticleDOI
The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12-15 Years - United States, May 2021.
Megan J. Wallace,Kate R. Woodworth,Julia W. Gargano,Heather M. Scobie,Amy Blain,Danielle Moulia,Mary Chamberland,Nicole Reisman,Stephen C. Hadler,Jessica R. MacNeil,Doug Campos-Outcalt,Rebecca L. Morgan,Matthew F. Daley,Jose R. Romero,H. Keipp Talbot,Grace M. Lee,Beth P. Bell,Sara E. Oliver +17 more
TL;DR: The Pfizer-BioNTech COVID-19 (BNT162b2) vaccine is a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine encoding the prefusion spike glycoprotein of SARS-CoV-2, the virus that causes COVID19 as mentioned in this paper.